Dragonfly, Bristol Myers Squibb to develop immunotherapies

By The Science Advisory Board staff writers

July 6, 2020 -- Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple sclerosis and neuroinflammatory targets.

Under the agreement, Bristol Myers Squibb will have the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary Trinket technology platform. Bristol Myers Squibb will pay Dragonfly a $55 million upfront payment, and Dragonfly will be eligible for additional development, regulatory, and milestone payments, as well as royalties on sales of approved product sales.

If you like this content, please share it with a colleague!

Related Reading

Immunic begins phase II immunotherapy for COVID-19
Immunic has enrolled the first COVID-19 patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase (DHODH) inhibitor.

Kleo, Green Cross collaborate on COVID-19 NK combination therapy
Kleo Pharmaceuticals is joining forces with Green Cross LabCell of South Korea to advance testing of natural killer (NK) cell therapies as a potential...

Inflammatory attack comes from an unexpected source in rheumatoid arthritis
Researchers have pinpointed immune cells called natural killer cells as an unexpected source of inflammatory proteins that contribute to rheumatoid arthritis....